EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell CarcinomaRitu Chaudhary, Christine H. Chung, Robbert J.C. Slebos et al.|Cancer Research Communications|2023Cited by 14
Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobin Park, Christine H. Chung, Jiannong Li et al.|Oral Oncology|2024Cited by 5
Immune landscape in molecular subtypes of human papillomavirus‐negative head and neck cancerMengyu Xie, Aik Choon Tan, Ritu Chaudhary et al.|Molecular Carcinogenesis|2023Cited by 4
Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).Robin Park, Christine H. Chung, F. Rind et al.|Journal of Clinical Oncology|2023Cited by 1
Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).Christine H. Chung, Aik Choon Tan, Graydon Moorhead et al.|Journal of Clinical Oncology|2023Cited by 1